Reaction

Tumour Necrosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,037 reports · 43 co-occurring drugs

As of the last recalculation, Tumour Necrosis appears in 1,037 FAERS reports alongside 43 co-occurring drug terms. The strongest observed disproportionality signal is TEMOZOLOMIDE (PRR 46.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Temozolomide	47	46.8	46.9
Bevacizumab	194	38.4	38.5
Sorafenib	32	31.9	31.9
Atezolizumab	46	24.8	24.9
Irinotecan Hydrochloride	15	23.7	23.8
Regorafenib	13	22.7	22.8
Oxaliplatin	76	22.1	22.1
Everolimus Tablets	17	20.7	20.7
Fluorouracil Cream, 0.5%	71	20.0	20.0
Fluorouracil	71	19.7	19.7
Cisplatin	71	19.5	19.5
Ado-Trastuzumab Emtansine	8	19.2	19.2
Imatinib Mesylate	24	17.7	17.7
Pazopanib Hydrochloride	23	17.4	17.4
Leucovorin Calcium	16	17.1	17.1
Sunitinib Malate	32	16.8	16.8
Paclitaxel	77	16.8	16.8
Paclitaxel (Aibumin-Bound)	63	16.3	16.3
Pembrolizumab	74	15.1	15.1
Everolimus	37	15.1	15.1
Pemetrexed Disodium	26	14.0	14.0
Lenvatinib	22	13.7	13.7
Carboplatin	75	12.7	12.7
Pemetrexed	13	12.3	12.3
Gemcitabine Hydrochloride	31	12.1	12.1
Etoposide	42	11.9	11.9
Vincristine Sulfate	17	11.8	11.8
Imatinib	10	11.5	11.5
Capecitabine	46	10.5	10.5
Ifosfamide	11	10.4	10.4
Panitumumab	8	10.3	10.3
Doxorubicin	43	10.1	10.1
Doxorubicin Hydrochloride	15	9.3	9.3
Gemcitabine	18	9.3	9.3
Nivolumab	43	9.3	9.3
Ipilimumab	19	9.0	9.0
Cabozantinib	21	8.9	8.9
Docetaxel Anhydrous	27	8.2	8.2
Docetaxel	27	8.2	8.2
Crizotinib	5	7.9	7.9
Axicabtagene Ciloleucel	3	6.1	6.1
Durvalumab	6	5.9	5.9
Trifluridine And Tipiracil	3	5.6	5.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.